It was previously reported that IDH1 and IDH2 mutation drives αKG loss and accumulation of its competitive inhibiting product: D‐2‐hydroxyglutarate (D‐2HG) and R‐2‐hydroxyglutarate (R‐2HG) in glioma.[3] However, these efforts were focused on the metabolic and epigenetic disturbance of these oncometabolites in both tumor cells and T cells, while inhibition of these two derivatives could strengthen anti‐tumor immunity by restoring impairments of T cell differentiation and proliferation. Here, IDH2 is linked to central nervous system cancer.